Medincell raises €48 million in private placement
#Medincell #private placement #€48 million #funding #long-acting injectables #biotech #capital raise #pharmaceuticals
📌 Key Takeaways
- Medincell secured €48 million through a private placement
- The funding will support the company's development of long-acting injectable drugs
- This capital increase strengthens Medincell's financial position for future growth
- The private placement reflects investor confidence in Medincell's technology platform
🏷️ Themes
Biotech Funding, Pharmaceutical Development
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil holds steady after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Medincell raises €48 million in private placement By Company News Published 03/06/2026, 02:04 AM Medincell raises €48 million in private placement 0 MEDCL -4.15% MONTPELLIER, France - Medincell (Euronext Paris:MEDCL) completed a private placement raising €48 million through an offering to institutional investors, the company said in a statement Wednesday. The biopharmaceutical company issued 2,370,000 new shares at €20.35 per share, representing a 10% discount to the March 5, 2026 closing price of €22.64. The new shares represent 7.1% of the company’s share capital prior to the placement and 6.6% following completion.The placement comes as Medincell shares have delivered strong returns, with a 59% gain over the past year and a 34% increase over the last six months, according to InvestingPro data. The company currently trades at a market capitalization of $870 million. Healthcare specialist investors including Perceptive Advisors, Kurma Growth Opportunities Fund, Affinity Asset Advisors and Polar Capital participated in the transaction alongside existing shareholders. According to the press release, Medincell intends to use the proceeds to expand partnering opportunities through additional programs, optimize economics of future partnerships with emphasis on downstream royalty participation, and strengthen its long-acting injectable technology platform through targeted innovation.The capital raise strengthens Medincell’s balance sheet, which shows liquid assets exceeding short-term obligations with a current ratio of 2.88. The company reported revenue of $38 million in the last twelve months with impressive...
Read full article at source